Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolism

Objectives. To compare the ability of different cyclodextrin polysulphate (CDPS) derivatives to affect human articular cartilage cell metabolism in vitro. Methods. OA chondrocytes were cultured in alginate and exposed to 5 µg/ml of 2,3,6-tri-O-methyl-β-cyclodextrin (ME-CD), 2,3-di-O-methyl-6-sulphate-β-cyclodextrin (ME-CD-6-S), 2,6-di-O-methyl-3-sulphate-β-cyclodextrin (ME-CD-3-S), (2-carboxyethyl)-β-CDPS (CE-CDPS), (2-hydroxypropyl)-β-CDPS (HP-CDPS), 6-monoamino-6-monodeoxy-β-CDPS (MA-CDPS) or β-CDPS for 5 days. Effects on IL-1-driven chondrocyte extracellular matrix (ECM) metabolism were assayed by analysis of the accumulation of aggrecan in the interterritorial matrix, IL-6 secretion and qPCR. MA-CDPS, HP-CDPS, CE-CDPS and CDPS were analysed for their in vitro effect on coagulation and their ability to activate platelets in an in vitro assay to detect possible cross-reactivity with heparin-induced thrombocytopenia (HIT) antibodies. Results. The monosulphated cyclodextrins ME-CD-6-S and -3-S failed to affect aggrecan synthesis and IL-6 secretion by the OA chondrocytes. Polysulphated cyclodextrins MA-CDPS, HP-CDPS, CE-CDPS and CDPS at 5 µg/ml concentrations, on the other hand, significantly induced aggrecan production and repressed IL-6 release by the chondrocytes in culture. aPTT and PT for all derivatives were lengthened for polysaccharide concentrations >50 µg/ml. Five micrograms per millilitre of β-CDPS concentrations that significantly modulated ECM ground substance production in vitro did not affect aPTT or PT. Furthermore, CE-CDPS, in contrast to MA-CDPS, HP-CDPS and CDPS, did not significantly activate platelets, suggesting a minimal potential to induce HIT thromboembolic accidents in vivo. Conclusions. CE-CDPS is a new, structurally adjusted, sulphated β-cyclodextrin derivative with preserved chondroprotective capacity and a promising safety profile.

[1]  D. Deforce,et al.  Differential expression of alphaB-crystallin and evidence of its role as a mediator of matrix gene expression in osteoarthritis. , 2009, Arthritis and rheumatism.

[2]  E. Vignon,et al.  Cyclodextrin polysulphate protects articular cartilage in experimental lapine knee osteoarthritis. , 2008, Osteoarthritis and cartilage.

[3]  H. Watson,et al.  The management of heparin‐induced thrombocytopenia , 2006, British journal of haematology.

[4]  D. Elewaut,et al.  Cyclodextrin polysulphates repress IL-1 and promote the accumulation of chondrocyte extracellular matrix. , 2005, Osteoarthritis and cartilage.

[5]  J. Hirsh,et al.  Treatment of heparin-induced thrombocytopenia: a critical review. , 2004, Archives of internal medicine.

[6]  P. Kongtawelert,et al.  Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo , 2004, Rheumatology International.

[7]  G. Verbruggen,et al.  Analysis of chondrocyte functional markers and pericellular matrix components by flow cytometry. , 2004, Methods in molecular medicine.

[8]  G. Verbruggen,et al.  Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. , 2003, Osteoarthritis and cartilage.

[9]  T. Warkentin,et al.  Heparin‐induced thrombocytopenia: pathogenesis and management , 2003, British journal of haematology.

[10]  G. Verbruggen,et al.  Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. , 2003, Arthritis and rheumatism.

[11]  N. Heddle,et al.  Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.

[12]  G. Verbruggen,et al.  Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. , 2002, Clinical and experimental rheumatology.

[13]  G. Verbruggen,et al.  Systems to Assess the Progression of Finger Joint Osteoarthritis and the Effects of Disease Modifying Osteoarthritis Drugs , 2002, Clinical Rheumatology.

[14]  P. B. Weisz,et al.  &bgr;-Cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury , 2002, Coronary artery disease.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  M. Vitale,et al.  Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. , 2001, Cytometry.

[17]  L. Horstman,et al.  A Flow Cytometric Assay of Platelet Activation Marker P-Selectin (CD62P) Distinguishes Heparin-induced Thrombocytopenia (HIT) from HIT with Thrombosis (HITT) , 1999, Thrombosis and Haemostasis.

[18]  L. de Ridder,et al.  Influence of polysulfated polysaccharides on aggrecans synthesized by differentiated human articular chondrocytes. , 1999, The Journal of rheumatology.

[19]  R. Mason,et al.  Chondrocyte cytokine and growth factor expression in murine osteoarthritis. , 1997, Osteoarthritis and cartilage.

[20]  J. Tyler,et al.  Insulin-like growth factor (IGF) receptor, IGF-I, interleukin-1 beta (IL-1 beta), and IL-6 mRNA expression in osteoarthritic and normal human cartilage. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  V. Stella,et al.  Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. , 1995, Journal of pharmaceutical sciences.

[22]  J. Amiral,et al.  Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases , 1995, Thrombosis and Haemostasis.

[23]  A. Greinacher,et al.  Heparin‐associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan , 1992, British journal of haematology.

[24]  G. Verbruggen,et al.  Intra-articular injection pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid. , 1992, Clinical and experimental rheumatology.

[25]  D K MacCallum,et al.  Culture and growth characteristics of chondrocytes encapsulated in alginate beads. , 1989, Connective tissue research.

[26]  G. Verbruggen,et al.  Influence of an oversulphated heparinoid upon hyaluronate metabolism of the human synovial cell in vivo. , 1979, The Journal of rheumatology.

[27]  G. Verbruggen,et al.  Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells. , 1977, Acta rhumatologica Belgica.

[28]  N. Schwartz,et al.  Stimulation of chondroitin sulfate proteoglycan production by chondrocytes in monolayer. , 1975, Connective tissue research.

[29]  T. Astrup,et al.  Polysaccharide Sulfuric Acids as Anticoagulants. , 1944 .